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OBJECTIVES: To determine the incremental cost per life
year saved (CLYS) for France, Germany and UK, of clopi-
dogrel versus aspirin in secondary prevention of ischemic
events (myocardial infarction, ischemic stroke, vascular
death) in three high-risk populations of atherothrombotic
patients (history of cardiac surgery, prior ischemic stroke
or myocardial infarction, hypercholesterolemia or dia-
betes) from the CAPRIE randomised clinical trial.
METHODS: A Markov model designed with several clin-
ical states calculated CLYS as the cost needed to achieve
an extra life year with clopidogrel compared with aspirin.
The model combined rates of clinical outcomes (fatal or
non-fatal) reported in CAPRIE, with survival data derived
from the Framingham database and costs of outcomes
assessed from external sources. Life expectancy was cor-
rected according to the level of risk of patients. The eco-
nomic analysis was performed with local unit costs from
the health care system perspective with a time horizon 
of two years. Both costs and beneﬁts were discounted
(according to local guidelines). CLYS obtained for high
risk populations were compared with CLYS calculated for
the overall CAPRIE population. RESULTS: For France,
when compared to CLYS obtained for overall population
(€15,907), CLYS for patients with history of prior cardiac
surgery was decreased by 90% (€1,570), CLYS for
patients with prior ischemic stroke or myocardial infarc-
tion by 55% (€7,202) and by 24% for CLYS for popu-
lation with hypercholesterolemia or diabetes (€12,018).
Similar decreases in ratios for these high-risk populations
were found in Germany and UK. CONCLUSION:
The economic analysis shows more favourable cost-
effectiveness results for high-risk populations compared
to overall CAPRIE population. All CLYS ﬁgures are
within acceptable ranges and compare favourably with
other therapeutic strategies for secondary prevention of
ischemic events.
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OBJECTIVES: The NAVIGATOR trial will evaluate the
impact of nateglinide and valsartan on the progression to
diabetes in subjects with impaired glucose tolerance at
high risk for a cardiovascular event. Investigators in this
trial include endocrinologists, cardiologists and general
internists. Although economic evaluations of clinical
trials typically adjust for country, little is known about
how physician-speciﬁc characteristics may affect ALOS.
Our objective was to determine which physician charac-
teristics would be independent predictors of ALOS for
myocardial infarction (MI). METHODS: We analyzed
responses from a survey of NAVIGATOR investigators to
determine factors associated with self-reported ALOS in
the treatment of MI. Candidate predictors in the multi-
ple regression model were physician age, sex, years since
graduation, medical specialty, practice environment, and
geographic region. This relationship was examined using
linear regression. RESULTS: 385 respondents with com-
plete data were included in the model. Physician age, 
sex, years since graduation, specialty of internal medicine,
practice setting (solo or group), and geographic region
met the criterion for inclusion in the multivariable model.
Male physicians reported an ALOS 3 days shorter than
female doctors (p = < .0001). Physicians in group prac-
tice were associated with a 1-day longer ALOS as com-
pared to hospital-afﬁliated physicians (p = < .0001). All
geographic regions except for Africa and Canada were 
signiﬁcantly associated with longer ALOS than the US
(Asia Paciﬁc 6 days, Eastern Europe 9, Europe 3.5, Latin
America 2) (p = < .0001 for all). CONCLUSIONS: For
NAVIGATOR investigators, physician sex, practice
setting and geographic region are predictors of ALOS. We
will adjust for physician characteristics in the economic
analysis of the NAVIGATOR trial. We conclude that mea-
suring physician characteristics should be incorporated
into multinational clinical trials.
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